Acticor Biotech Publishes Its 2022 Annual Results and Provid

Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients

Related Keywords

Israel , United Kingdom , Denmark , Spain , Paris , France General , France , Mediolanum , Lombardia , Italy , United States , Belgium , Czech Republic , Germany , French , Great Britain , Newton Biocapital , Corinne Le Goff , Patricia Zilliox , Venture Investment , French National Institute Of Health , European Medicines Agency , Ability Of The Company , European Union France , Institute Of Cardiovascular Sciences , Programme Investissements , University Of Birmingham United Kingdom , University Hospitals Birmingham , Given The Company , University Of Birmingham , Central Ethics Committee , Registration Document , Chief Executive Officer , Acticor Biotech , Assistance Publique H , European Union , Modified Rankin Scale , Biologic License Application , Agence Nationale De La Recherche , Cardiovascular Sciences , Annual General Meeting , General Meeting , French National Institute , Medical Research , Mirae Asset Capital , Euronext Growth Paris , Operating Officer , Diese Gold Aktie , Sichern Sie , Acticor , Biotech , Ublishes , 022 , Nnual , Results , Rovides , Update , Linical , Progress ,